Drugs / BCD-256
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07136389 | Mar 2025 → Jan 2026 overdue | systemic lupus erythematosus | Biocad | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-256 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136389 ↗ |
| Modality | Monoclonal antibody | “Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously” NCT07136389 ↗ |
| Route | Intravenous | “concentrate for solution for infusion intravenously” NCT07136389 ↗ |